Pregabalin
Product Images NDC 45865-108

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 45865-108). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Medsource Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Pdp-108 (Pdp 108)

Pdp-108 (Pdp 108)
This is a prescription for Pregabalin Capsules, 150MG, a generic for Lyrica CV, used to treat nerve and muscle pain. The medicine can cause dizziness. The medication is not transferable to anyone other than the patient for whom it was prescribed. There are four different Pregabalin Capsules listed, with different quantities and expiration dates. The prescription was filled at a controlled drug store.*
FDA Label Image

Figure 1 (Pregabalin Fig01)

Figure 1 (Pregabalin Fig01)
The text provided is a combination of numbers, symbols, and gibberish. It is not clear what data or information is being conveyed. Therefore, the description cannot be generated.*
FDA Label Image

Figure 2 (Pregabalin Fig02)

Figure 2 (Pregabalin Fig02)
This is a report showing the percentage of patients who improved their pain levels after taking Pregabalin 160 mg for 3 days. There are also some numbers indicating the improvement in pain from a baseline, but the context is not clear.*
FDA Label Image

Figure 3 (Pregabalin Fig03)

Figure 3 (Pregabalin Fig03)
FDA Label Image

Figure 4 (Pregabalin Fig04)

Figure 4 (Pregabalin Fig04)
FDA Label Image

Figure 5 (Pregabalin Fig05)

Figure 5 (Pregabalin Fig05)
This looks like a clinical trial report comparing the effectiveness of Pregabalin and Placebo in reducing pain in patients. The dosage of Pregabalin was 80mg three times a day and for Fregabalin, it was 100mg three times a day. The report mentions the percentage of patients who improved and the percentage of improvement in pain from the baseline.*
FDA Label Image

Figure 6 (Pregabalin Fig06)

Figure 6 (Pregabalin Fig06)
The text appears to be a table showing different studies conducted with different doses of medication, including a placebo group, and indicating statistical significance compared to the placebo. The table has various blank cells and some characters that are not readable.*
FDA Label Image

Figure 7 (Pregabalin Fig07)

Figure 7 (Pregabalin Fig07)
FDA Label Image

Figure 9 (Pregabalin Fig08)

Figure 9 (Pregabalin Fig08)
The chart shows the percentage of patient improvement in pain from the baseline with the daily dose of Pregabalin 300mg and 450mg compared to the placebo. The text does not provide any additional information.*
FDA Label Image

Figure 10 (Pregabalin Fig09)

Figure 10 (Pregabalin Fig09)
This may be a chart or graph displaying estimated percentages of subjects without LTR for two groups, Progabain and Placebo, over a period of 180 days. The percentages range from 0% to 100%. However, without further context or a clearer image, it is difficult to provide a more precise description.*
FDA Label Image

Figure 11 (Pregabalin Fig10)

Figure 11 (Pregabalin Fig10)
FDA Label Image

Figure 12 (Pregabalin Fig11)

Figure 12 (Pregabalin Fig11)
This text provides a chart with the percent of subjects who improved from baseline to week 16 using Pregabalin and Placebo. The percentages of improvement are listed on the y-axis and range from 100% to 280%. On the x-axis, there are increments of 10 starting from 210 to 270.*
FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

Cockcroft And Gault Equation (Pregabalin Formula)
This appears to be a formula or equation related to calculating creatinine clearance (CLCT) using variables such as age, weight, and serum creatinine level. The equation involves the calculation of [140 - age (years)] multiplied by weight (in kilograms), then multiplied by a factor of 0.85 for female patients. This product is then divided by 72 multiplied by the serum creatinine level (in milligrams per deciliter). The purpose of this formula likely relates to evaluating renal function or kidney health in patients.*
FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical Structure (Pregabalin Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.